WO2008139703A1 - Agent for treatment of pulmonary disease - Google Patents

Agent for treatment of pulmonary disease Download PDF

Info

Publication number
WO2008139703A1
WO2008139703A1 PCT/JP2008/001081 JP2008001081W WO2008139703A1 WO 2008139703 A1 WO2008139703 A1 WO 2008139703A1 JP 2008001081 W JP2008001081 W JP 2008001081W WO 2008139703 A1 WO2008139703 A1 WO 2008139703A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
agent
pulmonary disease
pulmonary diseases
disclosed
Prior art date
Application number
PCT/JP2008/001081
Other languages
French (fr)
Japanese (ja)
Inventor
Kensuke Egashira
Junji Kojima
Megumi Sakamoto
Original Assignee
Kyushu University, National University Corporation
Kowa Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation, Kowa Co., Ltd. filed Critical Kyushu University, National University Corporation
Priority to KR1020097021959A priority Critical patent/KR101530393B1/en
Priority to ES08751606T priority patent/ES2425969T3/en
Priority to CN2008800137806A priority patent/CN101668542B/en
Priority to US12/596,996 priority patent/US20100086615A1/en
Priority to EP08751606.8A priority patent/EP2140882B1/en
Priority to JP2009513998A priority patent/JP4896220B2/en
Priority to CA2685054A priority patent/CA2685054C/en
Publication of WO2008139703A1 publication Critical patent/WO2008139703A1/en
Priority to HK10108116.0A priority patent/HK1141708A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Abstract

Disclosed is a highly effective agent for treatment of pulmonary diseases with little side effects. Specifically disclosed is an agent for treatment of pulmonary diseases by endotracheal administration, which contains a biocompatible polymer nanoparticle containing an HMG-CoA reductase inhibitor.
PCT/JP2008/001081 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease WO2008139703A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020097021959A KR101530393B1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
ES08751606T ES2425969T3 (en) 2007-04-27 2008-04-25 Agent for the treatment of lung diseases
CN2008800137806A CN101668542B (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
US12/596,996 US20100086615A1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
EP08751606.8A EP2140882B1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
JP2009513998A JP4896220B2 (en) 2007-04-27 2008-04-25 Lung disease treatment
CA2685054A CA2685054C (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease
HK10108116.0A HK1141708A1 (en) 2007-04-27 2010-08-25 Agent for treatment of pulmonary disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007119553 2007-04-27
JP2007-119553 2007-04-27
JP2007155816 2007-06-13
JP2007-155816 2007-06-13

Publications (1)

Publication Number Publication Date
WO2008139703A1 true WO2008139703A1 (en) 2008-11-20

Family

ID=40001929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/001081 WO2008139703A1 (en) 2007-04-27 2008-04-25 Agent for treatment of pulmonary disease

Country Status (10)

Country Link
US (1) US20100086615A1 (en)
EP (1) EP2140882B1 (en)
JP (1) JP4896220B2 (en)
KR (1) KR101530393B1 (en)
CN (1) CN101668542B (en)
CA (1) CA2685054C (en)
ES (1) ES2425969T3 (en)
HK (1) HK1141708A1 (en)
PT (1) PT2140882E (en)
WO (1) WO2008139703A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (en) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン Biocompatible nanopolymer particles containing active ingredients for administration to the lung
JP2015164420A (en) * 2014-02-10 2015-09-17 公立大学法人首都大学東京 chromatin structure control agent
WO2021167088A1 (en) * 2020-02-21 2021-08-26 良和 中岡 Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2526927A1 (en) * 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biocompatible nano- and microparticles coated with stabilisers for pulmonary application
WO2016076227A1 (en) * 2014-11-10 2016-05-19 正明 伊井 Statin-encapsulated nanoparticle preparation for enhancing stem cell function, stem cell with enhanced function containing statin-encapsulated nanoparticle, and method for producing same
WO2017191808A1 (en) 2016-05-06 2017-11-09 学校法人大阪医科薬科大学 Statin-containing nanoparticle preparation for enhancing function of stem cells for treating inflammatory disease, and functionally enhanced stem cells containing same for treating inflammatory disease
KR20200130704A (en) * 2018-02-26 2020-11-19 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Drug delivery system
JP2019196342A (en) * 2018-05-10 2019-11-14 学校法人大阪医科薬科大学 Statin-encapsulated nanoparticle preparation, dental pulp-derived stem cells containing the same, and cell preparation containing the same
JP2022522229A (en) * 2019-03-29 2022-04-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Inhaled statins as bronchodilators to improve lung function in respiratory diseases

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS56122375A (en) 1980-02-04 1981-09-25 Merck & Co Inc Novel antihypercholesteremic compound* its intermediate and its manufacture
JPS572240A (en) 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
US4346227A (en) 1980-06-06 1982-08-24 Sankyo Company, Limited ML-236B Derivatives and their preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS60500015A (en) 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト Mevalolactone congeners and their derivatives, their production methods and pharmaceutical compositions containing them
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
EP0304063A2 (en) 1987-08-20 1989-02-22 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JPH0358967A (en) 1989-07-21 1991-03-14 Warner Lambert Co (r-(r.,r.))-2-(4-fluorophenyl)-beta,delta- dihydroxy-5-(1-methylethyl)-3-phenyl -4-((phenylamino)carbonyl)-1h- pyrrole-1-heptanic acid, lactone thereof and salt thereof
US5102888A (en) 1987-08-20 1992-04-07 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases
JPH05178841A (en) 1991-07-01 1993-07-20 Shionogi & Co Ltd Pyrimidine derivative
WO2000048626A2 (en) * 1999-02-17 2000-08-24 University Of Washington Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
JP2003275281A (en) 2002-03-20 2003-09-30 Hosokawa Micron Corp Production method for composite particle containing drug
JP2004521152A (en) * 2000-05-16 2004-07-15 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） Materials based on biodegradable polymers and methods for their production
JP2004262810A (en) 2003-02-28 2004-09-24 Hosokawa Funtai Gijutsu Kenkyusho:Kk Method for producing medicine-containing composite fine particle and transpulmonary preparation
JP2006321763A (en) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk Biocompatibilie nanoparticle and method for production of the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
WO2003049701A2 (en) * 2001-12-10 2003-06-19 Spherics, Inc. Methods and products useful in the formation and isolation of microparticles
US20050191357A1 (en) * 2002-03-20 2005-09-01 Yoshiaki Kawashima Method of manufacturing chemical-containing composite particles
CA2488499C (en) * 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
US7183285B2 (en) * 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
AU2006330627A1 (en) * 2005-12-16 2007-07-05 University Of Kansas Nanoclusters for delivery of therapeutics
GB0619500D0 (en) * 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS57163374A (en) 1979-06-15 1982-10-07 Merck & Co Inc Hypocholesterolemic fermentation product and manufacture
JPS56122375A (en) 1980-02-04 1981-09-25 Merck & Co Inc Novel antihypercholesteremic compound* its intermediate and its manufacture
JPS572240A (en) 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
US4346227A (en) 1980-06-06 1982-08-24 Sankyo Company, Limited ML-236B Derivatives and their preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS60500015A (en) 1982-11-22 1985-01-10 サンド・アクチエンゲゼルシヤフト Mevalolactone congeners and their derivatives, their production methods and pharmaceutical compositions containing them
US4739073A (en) 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
JP2569746B2 (en) 1987-08-20 1997-01-08 日産化学工業株式会社 Quinoline mevalonolactones
US5102888A (en) 1987-08-20 1992-04-07 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones useful for treating hyperlipidemia and related diseases
EP0304063A2 (en) 1987-08-20 1989-02-22 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US5856336A (en) 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
JPH0358967A (en) 1989-07-21 1991-03-14 Warner Lambert Co (r-(r.,r.))-2-(4-fluorophenyl)-beta,delta- dihydroxy-5-(1-methylethyl)-3-phenyl -4-((phenylamino)carbonyl)-1h- pyrrole-1-heptanic acid, lactone thereof and salt thereof
US5273995A (en) 1989-07-21 1993-12-28 Warner-Lambert Company [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino) carbonyl]- 1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof
JPH05178841A (en) 1991-07-01 1993-07-20 Shionogi & Co Ltd Pyrimidine derivative
US5260440A (en) 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2000048626A2 (en) * 1999-02-17 2000-08-24 University Of Washington Aerosol compositions of hmg-coa reductase inhibitors for inhibiting inflammation associated with pulmonary disease
JP2004521152A (en) * 2000-05-16 2004-07-15 サントル ナシオナル ドゥ ラ ルシェルシェサイアンティフィク（セエヌエールエス） Materials based on biodegradable polymers and methods for their production
JP2003275281A (en) 2002-03-20 2003-09-30 Hosokawa Micron Corp Production method for composite particle containing drug
JP2004262810A (en) 2003-02-28 2004-09-24 Hosokawa Funtai Gijutsu Kenkyusho:Kk Method for producing medicine-containing composite fine particle and transpulmonary preparation
JP2006321763A (en) 2005-05-20 2006-11-30 Hosokawa Funtai Gijutsu Kenkyusho:Kk Biocompatibilie nanoparticle and method for production of the same

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Nanospheres tailored to inhalation devices", MANUFACTURING CHEMIST, vol. 77, no. 9, September 2006 (2006-09-01), pages 75 - 76, 78, XP008119399 *
BANDO Y. ET AL.: "Choki Kecchu Tairyusei o Mokuteki to shita Seibunkaisei Kobunshi Nanosphere no Sekkei", THE PHARMACEUTICAL SOCIETY OF JAPAN NENKAI YOSHISHU, vol. 127TH, no. 3, 5 March 2007 (2007-03-05), pages 126 + ABSTR. NO. 29P1-AM293 *
GINA GUIDELINE, 2006
GOLD GUIDELINE, 2006
GOODMAN; GILMAN: "Pharmacological Basis of Therapeutics", 2001, MCGRAW HILL
HOTHERSALL E. ET AL., THORAX, vol. 61, 2006, pages 729 - 734
JOURNAL OF THE SOCIETY OF POWDER TECHNOLOGY, vol. 42, no. 11, 2005, pages 765 - 772
MANCINI GBJ ET AL., J. AM. COLL. CARDIOL., vol. 47, 2006, pages 2554 - 2560
MIZOE T. ET AL.: "Nano Ryushi Gan'yu Microsphere no Sekkei to DDS eno Oyo", SOCIETY OF POWDER TECHNOLOGY, JAPAN.FUNTAI KOGYO GIJUTSU KYOKAI GIJUTSU TORONKAI.TEXT, vol. 41ST, 2006, pages 19 - 20 *
OURNAL OF THE SOCIETY OF POWDER TECHNOLOGY, vol. 42, 2005, pages 765 - 772
POYNER E.A. ET AL.: "A comparative study on the pulmonary delivery of tobramycin encapsulated into liposomes and PLA microspheres following intravenous and endotracheal delivery", JOURNAL OF CONTROLLED RELEASE, vol. 35, no. 1, July 1995 (1995-07-01), pages 41 - 48, XP004037491 *
See also references of EP2140882A4
SOYSETH V. ET AL., EUR. RESPIR. J., vol. 29, 2007, pages 279 - 283
WALTER N. ET AL., PROC. AM. THORAC. SOC., vol. 3, 2006, pages 330 - 338

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014516044A (en) * 2011-05-25 2014-07-07 ユストゥス−リービッヒ−ウニヴェルジテート・ギーセン Biocompatible nanopolymer particles containing active ingredients for administration to the lung
JP2015164420A (en) * 2014-02-10 2015-09-17 公立大学法人首都大学東京 chromatin structure control agent
WO2021167088A1 (en) * 2020-02-21 2021-08-26 良和 中岡 Composition for alleviating pulmonary hypertension, method for predicting prognosis of pulmonary hypertension, method for assisting in determining severity of pulmonary hypertension, and method for assisting in diagnosing pulmonary hypertension

Also Published As

Publication number Publication date
EP2140882A4 (en) 2010-05-26
JPWO2008139703A1 (en) 2010-07-29
CN101668542B (en) 2012-06-27
KR20100015758A (en) 2010-02-12
HK1141708A1 (en) 2010-11-19
EP2140882B1 (en) 2013-08-14
ES2425969T3 (en) 2013-10-18
PT2140882E (en) 2013-09-30
US20100086615A1 (en) 2010-04-08
CA2685054A1 (en) 2008-11-20
CN101668542A (en) 2010-03-10
EP2140882A1 (en) 2010-01-06
JP4896220B2 (en) 2012-03-14
CA2685054C (en) 2014-11-04
KR101530393B1 (en) 2015-06-19

Similar Documents

Publication Publication Date Title
WO2008139703A1 (en) Agent for treatment of pulmonary disease
EP1937633B8 (en) Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2008070129A3 (en) Compositions and methods for the treatment of inflammatory disease
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007104789A3 (en) Amylin derivatives
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008040548A3 (en) Treatment for non-alcoholic-steatohepatitis
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
NZ589764A (en) NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2007087431A3 (en) Sublingual fentanyl spray
WO2009017837A3 (en) Sublingual fentanyl spray
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
WO2008022024A3 (en) Imidazole amines as inhibitors of beta-secretase
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
WO2009051119A1 (en) Pyrimidyl indoline compound
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
MX2009011712A (en) Enhanced formulations of lamotrigine.
WO2011058027A3 (en) N-9-substituted purine compounds, compositions and methods of use
WO2010066629A3 (en) Novel azaindoles
WO2009065596A3 (en) Use of mnk inhibitors for the treatment of alzheimer's disease
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880013780.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08751606

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009513998

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008751606

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097021959

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2685054

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE